Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
Date:11/1/2011

compounds, and the potential therapeutic and commercial potential of LX1031, LX1032, LX1033, LX2931, and LX4211. This press release also contains forward-looking statements relating to Lexicon's partnership discussions with third parties with respect to the development and commercialization of LX1032.  In addition, this press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, including with respect to LX1032, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whethe
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
2. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
3. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
4. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
5. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
6. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
7. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
9. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
11. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... BOSTON , Aug. 27, 2014  Columbia Laboratories, ... Company"), a provider of pharmaceutical development, clinical trial manufacturing, ... industry, today announced that it will participate at the ... Investment Conference, to be held in New ... conference at 11:15am on September 9, 2014 at the ...
(Date:8/27/2014)... and NINGBO, China , ... the Ningbo Menovo Pharmaceutical Co., Ltd, ("Menovo") today announced ... development of generic pharmaceuticals, primarily targeting the ... the agreement, Amerigen and Menovo will jointly develop products ... States . Menovo will be responsible for manufacturing ...
(Date:8/27/2014)... 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... financial results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over the ... for the quarter of $240,156 compared to net income of ... For the nine months ended June 30, 2014: ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
(Date:8/27/2014)... Photodynamic therapy (PDT, which uses topical agents and light ... (AKs, a common skin lesion caused by sun damage) ... liquid nitrogen to freeze lesions). , Author: ... Davis Medical Center, in Sacramento, and colleagues. , ... skin typically found on individuals with fair complexions who ...
(Date:8/27/2014)... play a key role in inflaming blood vessels and ... study at UCLA demonstrates that they may also contribute ... the small blood vessels in the lungs. , Using ... mimicking part of the main protein in high-density lipoprotein ... production of oxidized lipids in pulmonary hypertension. They also ...
(Date:8/27/2014)... August 27, 2014 The federal judge ... ) has extended the deadline for plaintiffs to enroll ... 2014 Order issued by U.S. District Judge David Katz ... enroll in the DePuy ASR Settlement Program must do ... Inc. ASR Hip Implant Products Liability Litigation – MDL ...
(Date:8/27/2014)... August 27, 2014 Ticket Down is a ... at Sun Life Stadium in Miami. The Brazilian national ... on September 5 at Sun Life Stadium in Miami Gardens, ... a rematch of the World Cup earlier this year when ... to injury. The Brazilian Soccer Federation announced earlier this week ...
(Date:8/27/2014)... 27, 2014 Connor Sports has ... World Cup in Spain at the Barcelona, Bilbao, Gran ... FIBA Equipment & Venue Centre Partner since 1994 and Official ... six courts will bear the Connor Sports logo and tagline ... globe on the ESPN broadcasts of the FIBA World Cup. ...
Breaking Medicine News(10 mins):Health News:Photodynamic therapy vs. cryotherapy for actinic keratoses 2Health News:Protein in 'good cholesterol' may be a key to treating pulmonary hypertension 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 3Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Cuts Ticket Prices on World Cup Rematch of Colombia vs. Brazil at Sun Life Stadium in Miami on Sept. 5th 2Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Cuts Ticket Prices on World Cup Rematch of Colombia vs. Brazil at Sun Life Stadium in Miami on Sept. 5th 3Health News:Connor Sports® Provides Six Custom Courts for 2014 FIBA World Cup - Time-Lapse Video of FIBA Courts Production Released 2Health News:Connor Sports® Provides Six Custom Courts for 2014 FIBA World Cup - Time-Lapse Video of FIBA Courts Production Released 3
... potent antioxidant , FRIDAY, Nov. 13 (HealthDay News) -- ... yellow curry ingredient curcumin, which is being tested in ... and Alzheimer,s disease. , Curcumin, the active ingredient in ... juices in the gastrointestinal tract quickly destroy curcumin, which ...
... one than age, study finds , FRIDAY, Nov. 13 (HealthDay News) ... than in 50-year-old women, according to a study that found that ... The analysis of data from the Million Women Study of 1.3 ... women aged 50 to 54, the risk of hip fracture of ...
... 13 A surprisingly easy and low-cost system of ... with Crohn,s disease and ulcerative colitis, a study released ... an online information network, allowing caregivers to systematically collect ... and their effectiveness. Creation and use of this ...
... Inc. (Nasdaq: BMRN ) announced today that Genzyme ... detected foreign particles in some products filled at the ... not exposed to foreign particles during product administration, Genzyme ... treating patients with enzyme replacement products that it markets, ...
... Nov. 13 Americans may realize that they have a ... underestimate the cost of care, believe government programs cover more ... deal with their own potential care. A national survey of ... of LTC Awareness Month (November) and John Hancock,s "Know Your ...
... for hepatitis and more , FRIDAY, Nov. 13 (HealthDay ... an extensive database about proteins produced by genes in ... the foundation for new treatments for liver disease. , ... kind for any organ, the researchers examined 10 liver-tissue ...
Cached Medicine News:Health News:'Global Bulletin Board' Shows Promise in Child Health 2Health News:'Global Bulletin Board' Shows Promise in Child Health 3Health News:'Global Bulletin Board' Shows Promise in Child Health 4Health News:Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme 2Health News:Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme 3Health News:LTC Awareness Month Finds Americans Still in Dark about Long-Term Care 2Health News:LTC Awareness Month Finds Americans Still in Dark about Long-Term Care 3Health News:LTC Awareness Month Finds Americans Still in Dark about Long-Term Care 4Health News:LTC Awareness Month Finds Americans Still in Dark about Long-Term Care 5Health News:LTC Awareness Month Finds Americans Still in Dark about Long-Term Care 6
... Designs ROM post-operative knee braces are designed ... rehabilitation. , ,Adjustable and versatile, ROM ... for health care professionals. The braces are ... feature quick dial combination hinges that allow ...
... Neuroprene™ soft supports are a convenient, ... proprioceptive taping for common orthopedic conditions/instabilities. ... provide specific compression and lateral to ... (proprioceptors) in the skin and soft ...
... The Deluxe Heavy Duty Drop Lock Post Operative ... pin hinge with a spring loaded drop lock ... arms and contoured plates prevent the brace from ... a tibial offset for anatomical alignment that controls ...
... might just be the world's most versatile ... support, post-op/rehab support, or both, Flex is ... Accutrac™ ROM hinges control flexion and extension ... durability while being heat-moldable to accommodate changes ...
Medicine Products: